Department of Pediatrics, Severance Hospital, Institute of Allergy, Brain Korea 21 PLUS Project for Medical Science, Yonsei University College of Medicine, Seoul, Korea
Copyright © 2016 The Korean Society of Critical Care Medicine
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Data are presented as the median (interquartile range) or number of patients (percentage).
p-values are from the chi-square test or Mann–Whitney U test used to compare differences between the survivor and non-survivor groups.
ICU: intensive care unit; PRISM: pediatric risk of mortality; PIM: pediatric index of mortality; DNI: delta neutrophil index; WBC: white blood cells; Hb: hemoglobin; ANC: absolute neutrophil count; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; PT: prothrombin time; INR: international normalized ratio; aPTT: activated partial thromboplastin time; ATIII: antithrombin III.
Data are presented as the median (interquartile range) or number of patients (percentage).
p-values are from the chi-square test or Kruskal–Wallis test used to compare differences between DNI groups.
ICU: intensive care unit, PRISM: pediatric risk of mortality, PIM: pediatric index of mortality, DNI: delta neutrophil, WBC: white blood cells, ANC: absolute neutrophil count, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, PT: prothrombin time, INR: international normalized ratio, aPTT: activated partial thromboplastin time, ATIII: antithrombin III.
| Survivor (n = 422) | Non-survivor (n = 94) | p-value | |
|---|---|---|---|
| Clinical characteristics | |||
| Age (years) | 2.5 (0.9-7.1) | 4.6 (1.6-10.2) | 0.006 |
| Male sex | 248 (58.8) | 60 (63.8) | 0.416 |
| Positive blood culture | 18 (4.3) | 11 (12.5) | 0.009 |
| Positive sputum culture | 64 (16.7) | 10 (12.5) | 0.405 |
| Mechanical ventilation (1 h) | 377 (89.3) | 90 (96.8) | 0.028 |
| Mechanical ventilation (24 h) | 298 (70.6) | 81 (87.1) | 0.001 |
| Length of ICU stay (days) | 9.5 (5-20) | 6.0 (2-15) | 0.001 |
| ICU scoring systems | |||
| PRISM III | 5 (2-10) | 19 (10-28) | < 0.001 |
| PIM2 (%) | 9.6 (5.1-26.9) | 45.7 (22.2-81.3) | < 0.001 |
| PIM3 (%) | 6.7 (3.7-15.4) | 32.4 (16.8-82.5) | < 0.001 |
| Hematologic variables | |||
| DNI (%) | 1.2 (0-4.3) | 9.5 (2.3-20.8) | < 0.001 |
| WBC (103/μL) | 11160 (6913-17083) | 8355 (3348-17968) | 0.001 |
| Hb (g/dL) | 10.5 ± 1.9 | 10.1 ± 2.8 | 0.140 |
| ANC (/μL) | 7730 (4140-12735) | 5415 (2119-12633) | 0.019 |
| Platelets (103/μL) | 295.5 (178.5-428.3) | 136.0 (60.0-266.3) | < 0.001 |
| ESR (mm/hr) | 12.0 (2-31) | 4.0 (2-31) | 0.173 |
| CRP (mg/L) | 8.0 (1.8-38.0) | 25.0 (8.9-118.9) | < 0.001 |
| Coagulation parameters | |||
| PT (sec) | 12.5 (11.4-14.0) | 15.2 (12.2-20.8) | < 0.001 |
| INR | 1.1 (1.0-1.2) | 1.4 (1.1-1.8) | < 0.001 |
| aPTT (sec) | 32.4 (28.3-38.0) | 45.1 (30.4-79.5) | < 0.001 |
| Fibrinogen (mg/dL) | 258 (181-347) | 218 (134-320) | 0.096 |
| D-dimer (ng/mL) | 636 (305-1328) | 1111 (453-3663) | 0.001 |
| ATIII (%) | 88 (67-106) | 72 (56-104) | 0.109 |
| Lactate | 1.4 (0.9-2.4) | 5.2 (1.9-14.3) | < 0.001 |
| No increase in DNI (< 5) (n = 366) | Low DNI (5-20) (n = 111) | Intermediate-high DNI (> 20) (n = 39) | p-value | |
|---|---|---|---|---|
| Clinical characteristics | ||||
| Age (years) | 2.39 (0.98-6.61) | 3.43 (1.38-7.9) | 7.48 (3.02-10.56) | 0.001 |
| Male sex | 212 (57.9) | 68 (61.3) | 28 (71.8) | 0.608 |
| Survivors | 317 (86.6) | 67 (60.4) | 27 (69.2) | < 0.001 |
| Mechanical ventilation | 246 (67.2) | 99 (90.0) | 34 (87.2) | < 0.001 |
| ICU scoring systems | ||||
| PRISM III | 5 (1.0-10.0) | 10.0 (6.0-18.0) | 20.0 (10.0-31.0) | < 0.001 |
| PIM2 | 10.2 (5.1-27.6) | 21.2 (7.5-45.1) | 48.1 (8.7-91.7) | < 0.001 |
| PIM3 | 7.1 (3.6-15.9) | 12.8 (5.4-29.3) | 43.8 (6.8-93.2) | < 0.001 |
| Hematologic variables | ||||
| WBC (103/μL) | 10.78 (6.58-15.68) | 13.29 (6.84-23.86) | 6.68 (2.46-14.9) | 0.003 |
| ANC (/μL) | 7,441 (3,890-11,880) | 9,740 (4,980-19,340) | 4,170 (1,294-9,804) | 0.005 |
| Hb (g/dL) | 10.4 (9.3-11.6) | 10.6 (8.9-12.0) | 9.9 (7.8-11.3) | 0.213 |
| Platelets (103/μL) | 295 (181-437) | 223 (92-380) | 132 (55-251) | < 0.001 |
| ESR (mm/h) | 12.0 (2.0-31.0) | 9.5 (2.0-34.2) | 5.5 (2.0-35.8) | 0.668 |
| CRP (mg/L) | 7.4 (1.7-31.2) | 19.2 (4.9-71.3) | 98.5 (16.1-167.6) | < 0.001 |
| Coagulation parameters | ||||
| PT (sec) | 12.5 (11.4-14.0) | 13.0 (11.6-16.2) | 16.3 (13.5-22.6) | < 0.001 |
| INR | 1.10 (1.00-1.21) | 1.13 (1.02-1.42) | 1.45 (1.23-1.98) | < 0.001 |
| aPTT (sec) | 31.7 (28.1-37.9) | 35.7 (29.7-52.3) | 45.8 (32.7-61.4) | < 0.001 |
| D-dimer (ng/mL) | 539.0 (284-1194) | 946.5 (543-2718) | 1444.5 (449-7603) | < 0.001 |
| ATIII (%) | 88.5 (67.0-107.0) | 79.0 (60.5-104.8) | 69.0 (58.3-82.0) | 0.013 |
| Lactate (mmol/L) | 1.4 (0.9-2.4) | 2.1 (1.2-4.9) | 4.6 (1.6-14.0) | < 0.001 |
Data are presented as the median (interquartile range) or number of patients (percentage). p-values are from the chi-square test or Mann–Whitney ICU: intensive care unit; PRISM: pediatric risk of mortality; PIM: pediatric index of mortality; DNI: delta neutrophil index; WBC: white blood cells; Hb: hemoglobin; ANC: absolute neutrophil count; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; PT: prothrombin time; INR: international normalized ratio; aPTT: activated partial thromboplastin time; ATIII: antithrombin III.
Data are presented as the median (interquartile range) or number of patients (percentage). p-values are from the chi-square test or Kruskal–Wallis test used to compare differences between DNI groups. ICU: intensive care unit, PRISM: pediatric risk of mortality, PIM: pediatric index of mortality, DNI: delta neutrophil, WBC: white blood cells, ANC: absolute neutrophil count, ESR: erythrocyte sedimentation rate, CRP: C-reactive protein, PT: prothrombin time, INR: international normalized ratio, aPTT: activated partial thromboplastin time, ATIII: antithrombin III.